A Study to Assess a PI3Kδ Inhibitor (IOA-244) in Patients With Metastatic Cancers
Status:
Recruiting
Trial end date:
2023-04-01
Target enrollment:
Participant gender:
Summary
The objective of study IOA-244-101 is to determine whether IOA-244 is safe and tolerable in
cancer patients (Part A). In addition, the study will assess whether IOA-244 can increase the
anti-tumour immune response in patients both as monotherapy and in combination with
pemetrexed/cisplatin (Part B).
Participants will receive IOA-244 for a period of 6 months. After treatment completion,
participants will continue in the study for a follow-up period of 6 months.